

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Soumya P. Sahoo, et al.	
Serial No.:	10/021,667	Case No.:20768
Filed:	October 29, 2001	
For:	BENZOPYRANCARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES AND LIPID DISORDERS	

Art Unit:
1626Examiner:
Taofiq A. SololaCommissioner for Patents
Washington, D.C. 20231*Ms. enter to 6/6/03*
REQUEST FOR RECONSIDERATION OF FINALITY
OF OFFICE ACTION

This Request is submitted in response to the Final Office Action that was mailed May 19, 2003.

Applicants respectfully submit that the Final Office Action is premature and request the Examiner to withdraw the finality of the office action in accordance with MPEP§706.07 (d).

This Office Action should be a non-final action because it does not meet the requirements of MPEP§706.07. The second paragraph of MPEP§706.07 (a) provides the following explanation of whether or not a second office action is final:

U.S.S.N.
CASE NO.
Page No.10/021,667
20768
2

Under present practice, second or any subsequent actions on the merits shall be final, except where the examiner introduces a new ground of rejection that is neither necessitated by applicant's amendment of the claims nor based on information submitted in an information disclosure statement filed during the period set forth in 37 CFR 1.9 (c) with the fee set forth in 37 CFR 1.17(p).

No prior art rejection was made in the first Office Action. In the present Office Action, the Examiner rejected the claims under sections 35 USC§102 and 35 USC§103 over references that were considered when the first Office Action was prepared. The Clemens et al reference (US Patent 5,563,164) that was cited in the current Office Action is the US equivalent of WO 95/17183, which was also considered by the Examiner in the preparation of the first Office Action.

The Examiner states that the new rejections are necessitated by the applicants' amendments that were filed in response to the first office action. However, the previous amendments did not make the claims broader than the claims that were before the examiner in the preparation of the first office action. Therefore, the prior art rejections that are applied in this Office Action are not more necessary now than at the time of the previous office action. The scope of the applicants' claims has not been expanded. The amendments made by the applicants could not have necessitated these new rejections.


U.S.S.N.
CASE NO.
Page No.

10/021,667
20768
3

Therefore, the current office action should be a second non-final Office Action.

Applicants respectfully request a non-final Office Action. If the Examiner wishes to discuss any matter relating to this application, he is invited to telephone the undersigned attorney.

Respectfully submitted,

By 

James L. McGinnis
Reg. No. 34,387
Attorney for Applicant
MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(732) 594-0641

Date: May 29, 2003



Merck & Co., Inc.
P.O. Box 2000
Rahway, NJ 07065

Patent Department

Facsimile Cover Sheet

TODAY'S DATE: _____

PLEASE DELIVER THE FOLLOWING MESSAGE TO:

Examiners Name: Taofiq A. Solola

Examiner's fax number: 703-308-4556

Group number: 1626

FAX RECEIVED

MAY 30 2003

GROUP 1600

THIS MESSAGE IS FROM:

Name: James L. McGinnis

Phone No.: (732) 594-0641

Fax No.: (732) 594-4720

OFFICIAL

Mail Location: RY60-30

RE: Applicants: Soumya P. Sahoo, et al.

Case No.: 20768

Serial No.: 10/021,667

Filed: October 29, 2001

Title: BENZOPYRAN CARBOXYLIC ACID DERIVATIVES
FOR THE TREATMENT OF DIABETES AND LIPID
DISORDERS

NUMBER OF PAGES BEING TRANSMITTED (INCLUDING COVER): 4

IF YOU DO NOT RECEIVE ALL OF THE PAGES, PLEASE CALL (732) 594-0641

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below

Violet Burgess 5-29-03
Type or print name of person signing certification